marked.bio

anti-CTLA-4 antibody ยท antibody

gotistobart

1 active trials across 3 of our biomarkers, targeting CTLA-4. Not approved for any biomarker on marked.bio yet.

Also known as BNT316, ONC-392.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 1 1 Phase 1
EGFR exon 19 deletion / L858R 1 1 Phase 1
RET fusion or mutation 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of gotistobart.

  1. BioNTech 1

Trials

1 of 1 trials shown

  1. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

    Recruiting Phase 1 BioNTech Started 2022Primary completion 2030-02 NCT05142189

    BNT116cemiplimabdocetaxelcarboplatinpaclitaxelgotistobartanti-B7-H3 antibody conjugated to topoisomerase I inhibitoranti-HER3 antibody conjugated to topoisomerase I inhibitorBispecific antibody for PD-L1 and VEGF-Aosimertinib FDA EUALK-inhibitor or RET-inhibitor

    Participants' NSCLC must have classical EGFR mutations, i.e., ex19Del or L858R.

    EGFR exon 19 deletion / L858RALK fusionRET fusion or mutationNon-Small Cell Lung Cancer